Web Analytics Made Easy - Statcounter

top of page

Multiple Myeloma Clinical Trials @ University of Chicago, IL

uchicago

CC-92480

CC-92480

ascent

ascent

mmrf

mmrf

CC-92480

CC-92480

1/20

Multiple Myeoma Clinical Trials Currently Recruiting

NCT04827563: Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

2021 - (R) NCT04827563

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma

2020 - (R) NCT04634552

Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma

NCT04394650: Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM

2020 - (R) NCT04394650

Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM

NCT04318327: Phase 1 - BCMA-directed CAR-T Cell Therapy in Adult Patients With RRMM

2020 - (R) NCT04318327

Phase 1 - BCMA-directed CAR-T Cell Therapy in Adult Patients With RRMM

NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 Relapsed Refractory Myeloma

2020 - (R) NCT04244656

Phase 1 -A Safety and Efficacy Study Evaluating CTX120 Relapsed Refractory Myeloma

NCT04184050: Phase 1/2: Dose Esc. & Dose Exp. of safety, Tolerability & PK of HPN217 in RRMM

2019 - (R) NCT04184050

Phase 1/2: Dose Esc. & Dose Exp. of safety, Tolerability & PK of HPN217 in RRMM

NCT04155749: Phase 1: Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma

2019 - (R) NCT04155749

Phase 1: Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma

NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2

2019 - (R) NCT04133636

Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2

NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002

2019 - (R) NCT03989414

Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002

NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in RRMM

2016 - (R) NCT02899052

Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in RRMM

NCT02884102: MMRF Molecular Profiling Protocol - Multiple Myeloma Research Foundation

2016 - (R) NCT02884102

MMRF Molecular Profiling Protocol - Multiple Myeloma Research Foundation

NCT02675452: Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML

2016 - (R) NCT02675452

Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML

NDMM

NCT04923893: Phase 3 - Bort/Len/Dex f/b Cilta-cel f/b Len/Dex NDMM- ( No ASCT planned ) CARTITUDE-5

2021 - (R) NCT04923893

Phase 3 - Bort/Len/Dex f/b Cilta-cel f/b Len/Dex NDMM- ( No ASCT planned ) CARTITUDE-5

NCT04108624: Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients

2019 - (R) NCT04108624

Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients

NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002

2019 - (R) NCT03989414

Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002

NCT03500445: Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) NDMM

2018 (R) NCT03500445

Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) NDMM

NCT03729804: Phase 3: KRd Versus VRd in Patients With Newly Diagnosed Multiple Myeloma (COBRA)

2018 - (R) NCT03729804

Phase 3: KRd Versus VRd in Patients With Newly Diagnosed Multiple Myeloma (COBRA)

NCT01208662- Phase 3 - DETERMINATION Trial: Delayed vs Early Transplant with RVd & Revlimid Maint.

2010 - (Active) NCT01208662

NCT01208662- Phase 3 - DETERMINATION Trial: Delayed vs Early Transplant with RVd & Revlimid Maint.

MGUS/SMM

NCT03289299 : Phase 2 - Agg. Smoldering Curative Approach Eval. Novel Therapies & Transplant ASCENT

2017 - (R) NCT03289299

Phase 2 - Agg. Smoldering Curative Approach Eval. Novel Therapies & Transplant ASCENT

United States - Myeloma Clinical Trials | MCT Index (themyelomaclinicaltrials.com)

bottom of page